Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells

• Published in: Journal of biomedical science 2010-09, Vol.17 (1), p.76-76, Article 76
• Main Authors: Sun, Pei-Chang, Tzao, Ching, Chen, Ban-Hen, Liu, Chen-Wei, Yu, Cheng-Ping, Jin, Jong-Shiaw
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Cancer; Cancer cells; Care and treatment; Cell Line, Tumor - drug effects; Cell Line, Tumor - physiology; Cell Proliferation - drug effects; Cell Separation; Chemotherapy, Adjuvant; Chromatin; Colon cancer; Colorectal cancer; Flow Cytometry; G1 Phase - drug effects; Gene expression; Histone Deacetylase Inhibitors - pharmacology; Histones; Humans; Hydroxamic Acids - pharmacology; Proteins; Studies; Transferases; Tumor proteins; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - metabolism
• ISSN: 1423-0127; 1021-7770; 1423-0127
• DOI: 10.1186/1423-0127-17-76

Histone deacetylases and histone acetyl transferases covalently modify histone proteins, consequentially altering chromatin architecture and gene expression. The effects of suberoylanilide hydroxamic acid, a HDAC inhibitor, on 320 HSR colon cells were assessed in 320 HSR colon cancer cells. Concentration and time-dependent inhibition of 320 HSR cell proliferation was observed. Treatment of 320 HSR cells with 5 μM SAHA for 72 h significantly inhibited their growth by 50% as compared to that of the control. Fluorescence-activated cell sorting analysis demonstrated significant inhibition of cell cycle progression (sub-G1 arrest) and induction of apoptosis upon various SAHA concentrations after 48 h. In addition, the anti-apoptosis proteins, survivin and Bcl-xL, were significantly inhibited by SAHA after 72 h of treatment. Immunocytochemistry analysis revealed that SAHA-resistant cells were positive for cyclin A (85%), ki-67 (100%), p53 (100%), survivin (100%), and p21 (90%) expression. Furthermore, a significant increase cyclin A-, Ki-67-, p53-, survivin-, and p21-positive cells were noted in SAHA-resistant tumor cells. Our results demonstrated for the first time in 320 HSR colon adenocarcinoma cells that SAHA might be considered as an adjuvant therapy for colon adenocarcinoma.